View All Documents & Correspondence
A Composition Comprising Quercetin, And Resveratrol And Uses Thereof
Abstract: The present disclosure relates to a composition comprising quercetin and resveratrol, which at particular w/w ratios synergistically enhances inhibition of alpha glucosidase activity. This composition can be useful in wellness products, and for protection against metabolic disease.
Notices, Deadlines & Correspondence
Patent Information
Applicants
ITC LIMITED
Inventors
1. FATIMA, Humaira
2. RADHAKRISHNAN, Yashwanth
Specification
Claims:1. A composition for alpha glucosidase inhibition, said composition comprising:
a. quercetin; and
b. resveratrol,
wherein quercetin to resveratrol w/w ratio in said composition is in the range of 9:1-2:3.
2. The composition as claimed in claim 1, wherein quercetin to resveratrol w/w ratio in said composition is in the range of 4:1- 1:1.
3. The composition as claimed in claim 2, wherein quercetin to resveratrol w/w ratio in said composition is selected from the group consisting of 4:1, 3:2, and 1:1.
4. The composition as claimed in claim 1, wherein quercetin concentration in said composition is in the range of 80-180µg/ml and resveratrol concentration in said composition is in the range of 20-120µg/ml.
5. The composition as claimed in claim 4, wherein quercetin concentration in said composition is in the range of 100-160µg/ml and resveratrol concentration in said composition is in the range of 40-100µg/ml.
6. The composition as claimed in any of the claims 1-5, further comprising suitable carriers, diluents, and excipients.
7. The composition as claimed in any of the claims 1-6, wherein said composition is for oral ingestion.
8. A method of preparing a composition as claimed in any of the claims 1-7.
9. A method of inhibiting alpha glucosidase, said method comprising:
a. obtaining a composition as claimed in any of the claims 1-7; and
b. contacting said composition with alpha glucosidase,
wherein said method inhibits alpha glucosidase activity.
10. A composition as claimed in any of the claims 1-6 for use in preparing formulations for inhibiting alpha glucosidase.
, Description:As Attached
Documents
Orders
| Section | Controller | Decision Date |
|---|---|---|
| U/S 15 Refusal | MEENA J | 2021-12-30 |
| u/s 15 Refusal | MEENA J | 2021-12-30 |
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | Form 5 [19-01-2016(online)].pdf | 2016-01-19 |
| 2 | Form 3 [19-01-2016(online)].pdf | 2016-01-19 |
| 3 | Drawing [19-01-2016(online)].pdf | 2016-01-19 |
| 4 | Description(Complete) [19-01-2016(online)].pdf | 2016-01-19 |
| 5 | 201641001820-Power of Attorney-230316.pdf | 2016-04-04 |
| 6 | 201641001820-Form 1-230316.pdf | 2016-04-04 |
| 7 | 201641001820-Correspondence-230316.pdf | 2016-04-04 |
| 8 | 201641002000-FORM 18 [03-12-2019(online)].pdf | 2019-12-03 |
| 9 | 201641002000-FER.pdf | 2020-07-29 |
| 10 | 201641002000-FORM 4(ii) [28-01-2021(online)].pdf | 2021-01-28 |
| 11 | 201641002000-OTHERS [28-04-2021(online)].pdf | 2021-04-28 |
| 12 | 201641002000-FER_SER_REPLY [28-04-2021(online)].pdf | 2021-04-28 |
| 13 | 201641002000-CLAIMS [28-04-2021(online)].pdf | 2021-04-28 |
| 14 | 201641002000-Correspondence to notify the Controller [01-09-2021(online)].pdf | 2021-09-01 |
| 15 | 201641002000-Written submissions and relevant documents [22-09-2021(online)].pdf | 2021-09-22 |
| 16 | 201641002000-US(14)-HearingNotice-(HearingDate-08-09-2021).pdf | 2021-10-17 |
Search Strategy
| 1 | 2020-07-2212-31-36E_22-07-2020.pdf |